These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 32917511)
21. Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice. Brod F; Miura K; Taylor I; Li Y; Marini A; Salman AM; Spencer AJ; Long CA; Biswas S Front Immunol; 2018; 9():2780. PubMed ID: 30564231 [TBL] [Abstract][Full Text] [Related]
23. A randomized feasibility trial comparing four antimalarial drug regimens to induce Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T Elife; 2018 Feb; 7():. PubMed ID: 29482720 [TBL] [Abstract][Full Text] [Related]
24. Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations. Ndiaye YD; Hartl DL; McGregor D; Badiane A; Fall FB; Daniels RF; Wirth DF; Ndiaye D; Volkman SK Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():12-22. PubMed ID: 34333350 [TBL] [Abstract][Full Text] [Related]
25. Malaria: prophylaxis and therapy. Leo YS; Chew SK; Allen DM; Monteiro EH Singapore Med J; 1994 Oct; 35(5):509-11. PubMed ID: 7701373 [TBL] [Abstract][Full Text] [Related]
26. Development of malaria transmission-blocking vaccines: from concept to product. Wu Y; Sinden RE; Churcher TS; Tsuboi T; Yusibov V Adv Parasitol; 2015 Jun; 89():109-52. PubMed ID: 26003037 [TBL] [Abstract][Full Text] [Related]
27. Malaria: progress, perils, and prospects for eradication. Greenwood BM; Fidock DA; Kyle DE; Kappe SH; Alonso PL; Collins FH; Duffy PE J Clin Invest; 2008 Apr; 118(4):1266-76. PubMed ID: 18382739 [TBL] [Abstract][Full Text] [Related]
28. Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction. Coelho CH; Rappuoli R; Hotez PJ; Duffy PE Trends Parasitol; 2019 Jul; 35(7):483-486. PubMed ID: 31153722 [TBL] [Abstract][Full Text] [Related]
29. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR; Malar J; 2011 Aug; 10():224. PubMed ID: 21816029 [TBL] [Abstract][Full Text] [Related]
30. The Hitchhiking Parasite: Why Human Movement Matters to Malaria Transmission and What We Can Do About It. Marshall JM; Bennett A; Kiware SS; Sturrock HJW Trends Parasitol; 2016 Oct; 32(10):752-755. PubMed ID: 27496331 [TBL] [Abstract][Full Text] [Related]
31. Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. Gunawardena S; Karunaweera ND Pathog Glob Health; 2015 May; 109(3):123-41. PubMed ID: 25943157 [TBL] [Abstract][Full Text] [Related]
33. Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Miura K; Jongert E; Deng B; Zhou L; Lusingu JP; Drakeley CJ; Fay MP; Long CA; Vekemans J Malar J; 2014 Jul; 13():263. PubMed ID: 25007730 [TBL] [Abstract][Full Text] [Related]
34. Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs. Delves MJ Future Med Chem; 2012 Dec; 4(18):2251-63. PubMed ID: 23234549 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan. Mahmoudi S; Keshavarz H Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979 [TBL] [Abstract][Full Text] [Related]
36. Mathematical study of the role of gametocytes and an imperfect vaccine on malaria transmission dynamics. Teboh-Ewungkem MI; Podder CN; Gumel AB Bull Math Biol; 2010 Jan; 72(1):63-93. PubMed ID: 19568725 [TBL] [Abstract][Full Text] [Related]
37. Understanding and maximising the community impact of seasonal malaria chemoprevention in Burkina Faso (INDIE-SMC): study protocol for a cluster randomised evaluation trial. Moreno M; Barry A; Gmeiner M; Yaro JB; Sermé SS; Byrne I; Ramjith J; Ouedraogo A; Soulama I; Grignard L; Soremekun S; Koele S; Ter Heine R; Ouedraogo AZ; Sawadogo J; Sanogo E; Ouedraogo IN; Hien D; Sirima SB; Bradley J; Bousema T; Drakeley C; Tiono AB BMJ Open; 2024 Mar; 14(3):e081682. PubMed ID: 38479748 [TBL] [Abstract][Full Text] [Related]
38. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084 [No Abstract] [Full Text] [Related]
39. A research agenda to underpin malaria eradication. Alonso PL; Brown G; Arevalo-Herrera M; Binka F; Chitnis C; Collins F; Doumbo OK; Greenwood B; Hall BF; Levine MM; Mendis K; Newman RD; Plowe CV; Rodríguez MH; Sinden R; Slutsker L; Tanner M PLoS Med; 2011 Jan; 8(1):e1000406. PubMed ID: 21311579 [TBL] [Abstract][Full Text] [Related]